ADVM - アバランシェ・バイオテクノロジ―ズ (Adverum Biotechnologies Inc.) アバランシェ・バイオテクノロジ―ズ

 ADVMのチャート


 ADVMの企業情報

symbol ADVM
会社名 Adverum Biotechnologies Inc (アバランシェ・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Adverum Biotechnologies Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research develop and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing specifically in process development and assay development.   アバランシェ・バイオテクノロジ―ズは、米国のバイオ医薬品会社。眼科疾患用の新規遺伝子治療薬の発見、開発および商業化に従事。主な製品は、滲出型加齢黄斑変性症の遺伝子治療薬「AVA-101」やX染色体連鎖性網膜分離症(XLRS)の遺伝子治療薬「AVA-311」。本社は、カリフォルニア州メンロ・パ―ク。   Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
本社所在地 1035 O'Brien Drive Menlo Park CA 94025 USA
代表者氏名 Paul B. Cleveland ポールB.クリーブランド
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-272-6269
設立年月日 38899
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 78人
url www.avalanchebiotech.com
nasdaq_url https://www.nasdaq.com/symbol/advm
adr_tso
EBITDA EBITDA(百万ドル) -65.87600
終値(lastsale) 5.51
時価総額(marketcap) 345444347.74
時価総額 時価総額(百万ドル) 359.86400
売上高 売上高(百万ドル) 1.63300
企業価値(EV) 企業価値(EV)(百万ドル) 124.98800
当期純利益 当期純利益(百万ドル) -54.46500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Adverum Biotechnologies Inc revenues decreased 23% to $709K. Net loss increased 31% to $36M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development -gross increase of 39% to $20.8M (expense) Stock-based Compensation in SGA increase from $1.5M to $6.1M (expense).

 ADVMのテクニカル分析


 ADVMのニュース

   Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com
   Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com
  11月12日の株式アナリストのアップグレード(ACAD、ADVM、AOBC、ATSG、BIDU、CLLS、DXPE、FEYE、FHB、FSBW)」 Stock Analysts’ Upgrades for November, 12th (ACAD, ADVM, AOBC, ATSG, BIDU, CLLS, DXPE, FEYE, FHB, FSBW)  2019/11/12 15:58:09 Modern Readers
「11月12日火曜日のストックアナリストのアップグレード:ACADIA Pharmaceuticals(NASDAQ:ACAD)は、BidaskClubのアナリストによって売り評価からホールド評価にアップグレードされました。AdverumBiotechnologies(NASDAQ:ADVM)は、BidaskClubのアナリストによってホールド評価からアップグレードされましたAmerican Outdoor Brands(NASDAQ:AOBC)は、BidaskClubのアナリストによって購入評価からアップグレードされました[…]
Stock Analysts’ upgrades for Tuesday, November 12th: ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at BidaskClub from a sell rating to a hold rating. Adverum Biotechnologies (NASDAQ:ADVM) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. American Outdoor Brands (NASDAQ:AOBC) was upgraded by analysts at BidaskClub from a buy rating […]
   Adverum Biotechnologies Enters Oversold Territory  2019/09/30 13:04:00 Zacks Investment Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why  2019/09/25 13:00:07 Zacks Investment Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
   Adverum Reports Data From Phase I Wet AMD Study, Stock Down  2019/09/13 14:06:00 Zacks Investment Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
   Adverum Shares Sink After Phase 1 Readout From Wet AMD Gene Therapy Trial  2019/09/12 15:30:37 Benzinga
Adverum Biotechnologies Inc (NASDAQ: ADVM ) shares were plunging Thursday following the presentation of data from its gene therapy trial at a conference. What Happened Adverum, a gene therapy company focusing on ocular and rare diseases, announced 24-week, Phase 1 clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 for wet age-related macular degeneration, or wet AMD. The actively traded, small-cap biotech said the patients achieved vision maintenance and improvements in retinal anatomy after a one-time intravitreal dose of ADVM-022 through week 24. More importantly, … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アバランシェ・バイオテクノロジ―ズ ADVM Adverum Biotechnologies Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)